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Introduction: Transplanting mesenchymal stromal cells (MSCs) or their derivatives into a neurodegenerative
environment is believed to be beneficial because of the trophic support, migratory guidance, immunosuppression,
and neurogenic stimuli they provide. SB623, a cell therapy for the treatment of chronic stroke, currently in a clinical
trial, is derived from bone marrow MSCs by using transient transfection with a vector encoding the human Notch1
intracellular domain. This creates a new phenotype, which is effective in experimental stroke, exhibits
immunosuppressive and angiogenic activity equal or superior to parental MSCs in vitro, and produces extracellular
matrix (ECM) that is exceptionally supportive for neural cell growth. The neuropoietic activity of SB623 and parental
MSCs has not been compared, and the SB623-derived neuropoietic mediators have not been identified.
Methods: SB623 or parental MSCs were cocultured with rat embryonic brain cortex cells on cell-derived ECM in a
previously characterized quantitative neuropoiesis assay. Changes in expression of rat neural differentiation markers
were quantified by using rat-specific qRT-PCR. Human mediators were identified by using expression profiling, an
enzymatic crosslinking activity, and functional interference studies by means of blocking antibodies, biologic
inhibitors, and siRNA. Cocultures were immunolabeled for presynaptic vesicular transporters to assess neuronal
specialization.
Results: Among six MSC/SB623 pairs, SB623 induced expression of rat neural precursor, oligodendrocyte, and
astrocyte markers on average 2.6 to 3 times stronger than did their parental MSCs. SB623 expressed significantly
higher FGF2, FGF1, and BMP4, and lower FGFR1 and FGFR2 levels; and human FGF1, FGF2, BMPs, and HGF were
implicated as neuropoietic mediators. Neural precursors grew faster on SB623- than on MSC-derived ECM. SB623
exhibited higher expression levels and crosslinking activity of tissue transglutaminase (TGM2). TGM2 silencing
reduced neural precursor growth on SB623-ECM. SB623 also promoted the induction of GABA-ergic, but not
glutamatergic, neurons more effectively than did MSCs.
Conclusions: These data demonstrate that SB623 cells tend to support neural cell growth more effectively than
their parental MSCs and identify both soluble and insoluble mediators responsible, at least in part, for enhanced
neuropoietic potency of SB623. The neuropoiesis assay is a useful tool for identifying beneficial factors produced by
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After the acute stroke, the evolution of ischemic tissue
and the restoration of neuronal functions continue for
months and even years [1] and include the long-lasting
enhancement of neurogenesis [2,3]. In contrast to normal
adult neurogenesis that supplies neurons for the olfactory
region and hippocampus, this injury-generated neurogen-
esis produces neurons that migrate toward damaged brain
tissue [4,5]. The vast majority of these neurons, however,
survive for only a few days [3], likely because of a hostile
and deficient environment in the penumbra and the lack
of connections. New cell therapeutic approaches, such as
intracranial transplantation of mesenchymal stromal cells
(MSCs), target the brain microenvironment by decreasing
the inflammation, augmenting angiogenesis, promoting
the formation and integration of newborn neurons, and
supporting neural tissue, as well as by encouraging syn-
aptic connection from damaged neurons (reviewed in
[6,7]). These effects are thought to be mediated primarily
via paracrine factors produced by the transplanted cells;
however, the precise mechanisms are still unknown.
SB623 cells, an MSC derivative, are currently in clinical
trial as an intracranial cell therapy for chronic stroke. They
are derived from MSCs by using transient transfection
with a vector encoding the human Notch1 intracellular
domain (NICD1), followed by a 1-week selection and sub-
sequent propagation. They demonstrate positive effects in
ischemic stroke and Parkinson animal models [8,9]. This
manufacturing process creates a cell population that ap-
pears superior to the parental MSC in benefits it provides
to the degenerating neural tissue. In in vitro studies com-
paring SB623 cells to their parental MSC, SB623 show
equal or better immunosuppressive properties [10], im-
proved angiogenic potency [11], more robust growth of
neural cells on SB623-derived extracellular matrix (ECM)
[12], and equal protection of neurons or hippocampal
slices from oxygen-glucose deprivation [13].
The main focus of the present study is to test whether
SB623 cells differ from the parental MSC population
in their neuropoietic potency (that is, in their ability
to stimulate the proliferation of neural precursors and
their differentiation into neurons and glia.
We recently characterized a microplate assay for quanti-
tative analysis of MSC-driven neuropoiesis [14]. The assay
uses direct coculturing of primary embryonic rat neural
cells with human MSCs on cell-derived ECM, which
serves as a ”universal” substrate for the serum-free growth
of cells with different attachment requirements. Within
1 week, MSCs cell number-dependently stimulate the
growth of rat neural precursors, astrocytes, oligoden-
drocytes, and neurons; this stimulation can be quanti-
fied by measuring mRNA expression of corresponding
rat markers directly from coculture lysates. The system
enables a quantitative comparison of MSC lots or MSCderivatives, as well as studying of both diffusible and
locally acting ECM-associated mediators of neural cell
growth.
Recently, MSCs have been shown to promote synaptic
transmission, both in vivo and in vitro [15,16]. In cul-
tures of embryonic cortical cells, the differentiation of
cortical neurons into glutamatergic and GABAergic is pre-
determined early, before neurons extend axonal processes
(reviewed in [17]). Subsequent neuronal differentiation,
cell-cell contact, and exposure to soluble factors [18,19] all
lead to the localized induction of presynaptic varicosities
representing complex assemblies of components of hemi-
presynapses, including either vesicular glutamate (VGLUT)
or vesicular GABA transporters (VGATs), which are re-
sponsible for the uptake of corresponding neurotransmit-
ters into synaptic vesicles. These presynapses subsequently
cluster postsynaptic hemisynapses in apposing dendrites
and together undergo both spatial and temporal dynamic
changes. Recently, MSCs were implicated in enhancing
GABAergic transmission in cocultures [16]. Here we com-
pared the effects of MSCs and SB623 by quantifying pre-
synaptic puncta in cocultures.
The question of why SB623 cell-derived ECM is more
neurosupportive is also addressed here. Tissue transglu-
taminase (TGM2) is a signature MSC protein [20], a
multifunctional enzyme best known for its transamidating
function, which causes the posttranslational modification
of substrates by de novo formation of covalent bonds.
TGM2 crosslinks itself to fibronectin and fibrinogen and
generates highly stable covalent protein heterocomplexes
in ECM (reviewed in [21]). This protein also has numer-
ous nonenzymatic activities; in particular, it functions in
ECM as an adaptor/scaffolding, thus promoting cell adhe-
sion and migration. TGM2 was recently found to be dif-
ferentially present in MSC- and SB623-ECM [22]. This
finding, together with our prior observations that SB623-
derived ECM is both more favorable for neural cell growth
and less “fragile” during purification than MSC-derived
ECM, prompted us to test the hypothesis that elevated
TGM2 levels contribute to the superior neurosupportive
properties of SB623-derived ECM.
Thus, the major goal of this study was to compare the
neuropoietic activity of SB623 cells with that of their
parental MSCs and identify some of the mediators of this
effect. The comparison was conducted (a) in direct cocul-
tures of either MSC or SB623 cells with rat neural cells,
allowing the identification of soluble and cell-surface-
associated human mediators, and (b) by culturing neural
cells on MSC- or SB623-derived ECM, allowing the
identification of insoluble, ECM-bound factors. These
approaches, in combination with blocking/neutralization
agents, were used to implicate specific human factors
in the SB623-enhanced induction of neural precursors,
astrocytes, and oligodendrocytes, whereas the effects on
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of presynaptic formation.
Materials and methods
MSC and SB623 cell preparations and culturing
MSCs were prepared from bone marrow aspirates pur-
chased from Lonza (Walkersville, MD, USA), which
obtained all the necessary consent forms; MSC and
SB623 cell preparation as well as their characterization
was previously described [12]. MSCs and SB623 from
eight donors were used in this study. All the donors
were young men 19 to 25 years old; the panel used here
included different races. For coculture experiments,
cryopreserved cell aliquots were thawed, washed, and
resuspended in a neural growth medium consisting of
basal medium for embryonic neuronal cells (Neurobasal)
supplemented with B27 and 0.5 mM L-alanyl-L-glutamine
(GlutaMAX) (NB/B27/GLX) (all from Invitrogen).
For other uses, cells were plated at 3 to 5 × 104/cm2 in
α-minimum essential medium (Mediatech, Inc., Manassas,
VA, USA) supplemented with fetal bovine serum (HyClone,
Logan, UT, USA) and penicillin/streptomycin (Invitrogen)
(αMEM/FBS/PS) and grown for various times. Specifically,
for mRNA preparation, cells were grown for 5 days and
then lysed; for measuring TGM2 activity in cell lysates,
cells were grown for 5 days and serum-starved for an add-
itional 2 days; for the preparation of conditioned medium,
cells were grown for 3 to 4 days, and then the medium
was replaced with NB for 1 hour and then again with fresh
NB for 24 hours, followed by conditioned medium collec-
tion and storing at −80°C. Culturing for ECM preparation
is described later.
Plate coating
For the comparison of MSC and SB623 potency in the
quantitative neuropoiesis coculture assay or for immuno-
fluorescence, plates were coated with SB623 cell-derived
ECM, as described previously [12]. In brief, SB623 cells
were plated at 3 × 104 cells/cm2 in 96-well plates (Corning
Inc., Corning, NY, USA) or on glass coverslips (Fisher
Scientific, Pittsburgh, PA, USA) placed into 12-well plates
(Corning). Cells were grown for 5 days, and then the
medium was changed to serum-free, and culturing continued
for 2 days. For comparison of MSC- and SB623-derived
ECM, or for studying TGM2 gene silencing, oxygen-
rich surface (CellBIND) 96-well plates (Corning) were
used instead of regular tissue culture-treated plates, and
the cells were grown for 6 days followed by serum
deprivation for 1 day. Cell removal and ECM purifica-
tion were done as described previously [12]. In brief,
cells were treated with 0.2% Triton X-100 (Sigma-Aldrich,
St. Louis, MO, USA), then 0.33% NH4OH (Sigma-
Aldrich), followed by soaking in PBS and storing at 4°C
for no longer than 3 weeks.Ornithine/fibronectin coating (Orn/Fn) was prepared
as described in [14].
Preparation of rat embryonic brain cortical cells
Rat embryonic day 18 (E18) brain cortex pairs were pur-
chased from BrainBits (Springfield, IL, USA), and a cell
suspension was prepared as described previously [14].
ECM-based quantitative neuropoietic assay
All ingredients (medium, test substances, human and rat
cells) were added to an intermediate uncoated 96-well
plate first, 2.2 times final amounts per well, each condition
in quadruplicates; the resulting suspensions were mixed.
ECM-coated plates were brought to room temperature,
and the PBS removed. Concentrations and cell densities
reported later are indicated as final. Rat neural cells were
plated at the constant density of 1.5 × 104 cells/cm2 (5 ×
103 cells/well); human cells were used at varying densities.
For the quantitative comparison of neuropoietic activities,
human cells were plated at 125, 250, and 500 cells/well,
resulting in human/rat cell ratios 1:40, 1:20, and 1:10. In
the testing of inhibitory substances, the human/rat cell
ratio was 1:25, or as indicated. Cell suspensions from
the intermediate plates were distributed to duplicated
ECM-coated culture plates at 100 μl/well. Cultures were
grown for 5 or 7 days, and then culture medium was
completely aspirated, and cells were lysed in 20 μl/well
lysis and RNA stabilization buffer (SideStep; Agilent
Technologies, Santa Clara, CA, USA) according to the
manufacturer’s protocol.
Gene expression quantification
To determine gene-expression levels in human cells,
mRNA was purified by using RNA purification kit
(RNeasy) and DNA- free RNA set, both from Qiagen
(Germantown, MD, USA), according to the manufacturer’s
instructions; and 5 ng of purified RNA was used per quan-
titative RT-PCR (qRT-PCR). One-step qRT-PCR was
performed by using QuantiTect Probe RT-PCR Master
Mix (Qiagen) and preoptimized Taqman assays (Applied
Biosystems/Life Technologies), according to the manu-
facturer’s protocol. Expression levels were normalized
to those of glyceraldehyde 3-phosphate dehydrogenase
(GAP). For the quantification of neuropoietic effects
exerted by human cells or ECM on rat neural cells, the
expression of rat neural markers or human GAP was
determined directly in SideStep lysates diluted in water
1:10, as described in [14].
The following Taqman expression assays were used: rat-
specific: nestin (Rn00564394_m1), GFAP (Rn00566603_
m1), and CNP (Rn01399463_m1); and human-specific:
GAP (4333764 F), BMP4 (Hs00370078_m1), FGF2 (Hs0
0266645_m1), FGF1 (Hs00265254_m1), FGFR1 (Hs0
0915142_m1), FGFR2 (Hs01552926_m1), EGF (Hs01099
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m1), and TGM2 (Hs00190278_m1).
Growth factor neutralization and gene silencing
experiments
Anti-FGF2 monoclonal antibodies, clone bFM1 (neutraliz-
ing) and clone bFM2 (nonneutralizing) were from Millipore
(Billerica, MA, USA). Polyclonal goat anti-FGF1, normal
goat IgG control (both used at 5 μg/ml), and recombinant
human noggin were all from R&D Systems. Recombinant
FGF1 and FGF2 (used at 5 ng/ml) were from Peprotech.
For silencing experiments, human cells were plated at
2 × 105 cells/well in six-well plates in αMEM/FBS. On the
next day, cells were transfected with siRNA, either ON-
TARGETplusSMARTpool human HGF siRNA, TGM2
siRNA, or control nontargeting pool by using a transfec-
tion reagent (DharmaFECT1) (all reagents from Thermo
Scientific Dharmacon, Lafayette, CO, USA) according to
the manufacturer’s instructions. The next day, cells were
harvested by trypsinization. The viability of all transfec-
tants was >90%. Cells to be tested in cocultures were then
washed once with αMEM/FBS and twice with NB. Cells to
be used for ECM production were plated into CellBind
96-well plates and grown for 6 days, and then serum-
starved for 1 day; and the ECM was purified.
Aliquots of all transfectants were also plated in αMEM/
FBS/PS to test the silencing efficiency on day 6 by using
qRT-PCR, as well as for controlling actual cell numbers by
using lactate dehydrogenase (LDH) assay in cell lysates.
LDH activity assay
For cell number normalization, LDH activity in cell lysates
was determined as described in [12] by using the Cytotox-
icity Detection Kit (Clontech Laboratories, Mountain View,
CA, USA).
Immunofluorescence and quantification of
hemi-presynapses
The detection of rat nestin, GFAP, and CNP was de-
scribed previously [14]. For the detection of vesicular
glutamate- and GABA-transporters (VGLUT and VGAT),
cells were plated on Orn/Fn-coated glass coverslips, cul-
tured for 7 and 11 days, respectively, and fixed with 4%
paraformaldehyde/5% sucrose. The coverslips were then
blocked with 3% bovine serum albumin/0.3% TritonX-100
(both from Sigma-Aldrich) for 1 hour and incubated with
rabbit anti-VGAT or guinea pig anti-VGLUT (both from
Synaptic Systems, Goettingen, Germany) for 1 hour. After
washing, the coverslips were incubated for 1 hour with
donkey DyLight 549-conjugated AffiniPure anti-rabbit F
(ab’)2 IgG fragments and Alexa Fluor 488-conjugated Affi-
niPure anti-Guinea Pig F(ab’)2 IgG fragments (Jackson
Immunoresearch). After washing, the slips were mounted
with ProLong Gold antifade reagent containing 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen). Fluores-
cence microscopy was done by using Nikon Eclipse50i
microscope (Nikon Instruments, Melville, NY, USA) and a
Nikon Digital Camera, DXM1200C.
For the quantification of immunostaining per positive
cell, neural cells were cultured either alone or with MSCs
or SB623 at human/rat cell ratio of 1:20 for either 5 days
(Nestin/DAPI and GFAP/DAPI staining) or 12 days (CNP/
DAPI staining). Images of duplicated cultures, two images
per culture (total, four fields), were acquired by using
100× magnification; and neuromarker signals were quanti-
fied by using ImageJ. The numbers of positively stained
cells were determined manually by overlaying an image of
immunostained culture with a corresponding DAPI image.
The results were expressed as staining per cell. For the
quantification of VGLUT- and VGAT-puncta, duplicated
cultures were set for each condition. Microphotographs of
10 fields (five fields per culture), which included easily
traceable neurites with punctated staining, were taken at
400× magnification by using the same exposure time for
each antigen. Maximum contrasted images were printed
at full page on a Bizhub 280 (Konica Minolta) printer, and
the numbers of puncta were counted per neurite length
between the first and last visible puncta on the image.
To prevent sampling bias, printed images were placed
at random order, and counting was done on unidentified
images. One to six neurite segments were counted per
image, and the numbers of puncta/100 μm were averaged.
The identity of printed images was then determined by
using the original digital image.
TGM2 activity assay
A 96-well plate was coated with poly-L-lysine (PLL;
Sigma-Aldrich) at 10 μg/ml in PBS overnight at 4°C, and
then rinsed once with PBS and once with water. Mono-
layers of MSCs or SB623 were rinsed in PBS and then lysed
in a mammalian cell lysis/extraction reagent (CelLytic M,
Sigma-Aldrich) for 15 minutes at room temperature, with
shaking. Lysates were centrifuged at 13,000 rpm for 15
minutes at 4°C, and supernatants immediately analyzed or
stored at −80°C. Cell lysate (10 μl) was added to 90 μl
TGM2 activity assay buffer consisting of 1% Triton-X100,
50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM DTT,
and 5 mM CaCl2, followed by the addition of 20 μl 2.5 mM
biotinylated cadaverine (B-Cad, Sigma-Aldrich). The plate
was incubated at room temperature with gentle shaking
for 30 minutes and rinsed twice for 5 minutes in 50 mM
Tris, 3 mM EDTA. The plate was then blocked for
30 minutes with 3% BSA/50 mM Tris; and horseradish
peroxidase-streptavidin conjugate (1:5,000, Jackson
Immunoresearch) was added for 30 minutes. After three
washes, 3,3′,5,5′-tetramethylbenzidine (1 × TMB Substrate
Solution; eBioscience) was added, and absorbance was
measured at 650 nm against a standard curve, which
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jugate. TGM2 activity was normalized to total protein
content in lysates, which was determined by using a
MicroBCA protein assay kit (ThermoScientific, Rockford,
IL, USA).
TGM2 Western blotting
MSCs and SB623 cells were grown in six-well plates,
and ECM prepared as described earlier. ECMs were
scraped and solubilized in 100 μl/well of Tris-Glycine
SDS sample buffer (Life Technologies), and then boiled
at 95°C for 5 minutes and centrifuged at 13,000 rpm for
15 minutes. Sample aliquots were electrophoresed on two
identical 4% to 20% Tris-Glycine gels (Life Technologies);
one was then transferred to nitrocellulose, and another
one stained with a Coomassie G-250-based solution
(SimplyBlue SafeStain, Invitrogen). The blot was blocked
in 5% milk in Tris-buffered saline with 1× Tween-20 for
2 hours at room temperature and incubated for 2 hours
with human-crossreactive mouse anti-guinea pig TGM2
monoclonal antibody (LifeSpan Biosciences). After three
washes, the blot was incubated with peroxidase-conjugated
donkey anti-mouse IgG antibody (Jackson Immunore-
search). TGM2 was visualized by using SuperSignal
WestPico (Thermo Scientific). Densitometry was per-
formed on the blot and on the stained gel by using
Alpha Innotech imager and ImageJ software. The TGM2
signal was normalized to the total protein in each
sample.
Statistics
Error bars indicate standard deviation, unless indi-
cated otherwise. Paired t test was used for calculating
P values. A P value of less than 0.05 was considered to
be significant.
Results
Comparison of neuropoietic activity of SB623 and MSCs
To observe differences in the neuropoietic potency of
MSCs versus SB623 by using immunostaining, cocultures
with rat embryonic cortex cells (human/rat cell ratio 1:10)
were grown on ECM-coated glass and stained for rat
neural markers. Time points were chosen based on our
previous study (Aizman et al. 2013), which character-
ized the growth and differentiation of neural cells/MSCs
cocultures. At these specific time points, the differences
between neural cells alone and cocultures were large,
and the protein expression of rat neural markers was
directly dependent on the numbers of MSCs and SB623
cells added.
Staining for rat nestin, a marker of neural precursors
and stem cells, on day 5 (Figure 1A, upper row of images)
demonstrated that in cocultures with SB623, nestin-
positive (Nes+) cells were present in higher quantities andwere brighter, compared with MSC cocultures, whereas in
the absence of human cells, only a few Nes+ cells were
seen, with less-developed processes. Staining for GFAP, an
astrocyte marker, on day 5 (Figure 1A, middle row) re-
vealed well-developed astrocytes present in both SB623
and MSC cocultures, whereas no staining was observed in
the absence of human cells. Immunostaining for an oligo-
dendrocyte marker, CNP, on day 12 (Figure 1A, lower
row) revealed extensive cytoplasmatic CNP staining in co-
cultures with SB623 cells, limited perinuclear staining in
cocultures with MSCs, and barely detectable staining in
the absence of human cells. Cocultures were also stained
for the neuronal marker MAP2, and no difference be-
tween MSC- and SB623-cocultures was detectable on days
5 and 9 in either the numbers of mature neurons or their
dendrite outgrowth (see Additional file 1: Figure S1).
To compare MSC with SB623 cocultures quantitatively,
we cocultured rat neural cells with three plating densities
of human cells (125, 250, and 500 cells/well) and no hu-
man cells, and performed qRT-PCR for rat neural markers
and human GAP (Figure 1B). Nestin and CNP, but not
GFAP, expression levels were higher in SB623 cocultures,
whereas human GAP levels were slightly higher in MSC
cocultures. To analyze the data further, levels of neural
marker expression in the absence of human cells were
subtracted, and the resulting levels of each neural marker
were normalized to corresponding human GAP for each
number of human cells per well. The three normalized
values were then averaged for either MSCs or SB623 co-
cultures and referred to as “neuropoietic coefficients”
(Figure 1C). According to Figure 1C, for example, Nes
neuropoietic coefficient of SB623 from Donor A (SB623-A)
was 3.6 times higher than that of MSC-A. Table 1 demon-
strates ratios of SB623- to MSC-neuropoietic coefficients
for six donor pairs. SB623 cell preparations induced the
three differentiation neuromarkers to a greater or similar,
but not lower, extent than did MSCs. The averages of all
three neuropoietic coefficients were found to be higher in
the group of six SB623s compared with the group of six
MSCs. Thus, overall, SB623 cells exhibited increased neu-
ropoietic coefficients, compared with their parental MSCs,
with some variability between donor pairs.
To support the qRT-PCR data, nestin, GFAP, and CNP
expression also was quantified by using immunostaining.
Image analyses were performed for cocultures with
MSCs and SB623 of one donor (represented in Table 1 as
Donor D) by measuring the total neuromarker staining in
a field and dividing the value by the number of positive
cells in the field (see Additional file 2: Figure S2). This
method detected significantly stronger GFAP and CNP
staining in cocultures with SB623 compared with the
staining in cocultures with MSCs, whereas nestin staining
trended higher (without reaching statistical significance)






































































Figure 1 Comparison of neuropoietic activity of SB623 and MSCs in cocultures with rat embryonic neural cells. (A) Rat neural cells
were grown in the presence or absence of MSCs or SB623 (rat/human cell ratio was 10:1) and immunostained for rat nestin (upper panel) and
GFAP (middle panel) on day 5, or for CNP on day 12. Nuclei were stained with DAPI (B) An example of microplate neuropoiesis assay data:
a comparison of rat neural differentiation marker induction in cocultures of rat cells with MSCs and SB623 from Donor A. Rat neural cells
(5,000/well) were cocultured with 500, 250, and 125 cells/well of either MSCs or SB623; and expression of rat-specific nestin, GFAP, and CNP,
and human-specific GAP was quantified by using qRT-PCR. Stimulation with 10% MSC-CM and no stimulation (“No add”) were used as positive
control and background, respectively. Relative units correspond to standard samples used in qPCR run. Error bars represent SD of biologic
duplicates. (C) Neuropoietic coefficients of MSCs and SB623 from Donor A were calculated based on data presented in (B) by first subtracting
the background expression of a corresponding neural marker and then normalizing the expression of the neural marker to the human GAP for
each number of human cells per well, followed by averaging normalized values. Error bars represent SD from three normalized values.
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Table 1 SB623-to-parental MSC ratios of neuropoietic
coefficients
Nes CNP GFAP
Donor A 3.6 3.2 1.3
Donor B 3.9 3.5 7.3
Donor C 1.1 2.6 1.1
Donor D 1.4 2.9 1.9
Donor E 5.5 2.1 1.8
Donor F 2.3 1.8 2
Average 3 2.7 2.6
SD 1.68 0.65 2.35
Neuropoietic coefficients characterize the ability of MSCs or SB623 to induce a
corresponding rat neural marker in defined conditions of the microplate
neuropoiesis coculture assay. Pairs of SB623 and parental MSCs from six
donors were compared in the assay; and neuropoietic coefficients for nestin,
GFAP, and CNP were calculated, as explained in Figure 1, based on qRT-PCR
data. The table represents ratios of SB623 to MSC coefficients for six donors;
average ratios and standard deviations (SD) are in bold.
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with neural cells alone.
Expression of neuropoietic growth factors in SB623/MSC
pairs
In preliminary experiments, we first selected neuropoietic
factors of interest. Factors were chosen based on their
expression in MSCs (based on prior publications) and
on the effectiveness of their recombinant forms in indu-
cing a neuropoietic response in our culture system. Then
we compared MSCs and SB623 cells for the mRNA ex-
pression of the most potent of these factors: FGF2, FGF1,
EGF, HGF, HB-EGF, BMP4, BMP2, and BMP6. We also
tested the expression of two FGF receptors predominantly
expressed by MSCs, FGFR1 and FGFR2. Table 2 sum-
marizes data from eight SB623/MSC pairs (provided in
Additional file 3: Table S1) by presenting the averaged
ratios of SB623-to-MSC expression levels. The data show
that FGF2, FGF1, and BMP4 levels increased, whereas
FGFR2 strongly and FGFR1 mildly decreased in SB623
compared with MSCs. These differences were statistically
significant. An FGF2 ELISA of conditioned medium de-
tected higher FGF2 levels in SB623 compared with MSCs
in four of six donors (donors C, D, E, and F; see Additional
file 4: Figure S3). EGF levels were higher in five and lower
in two of the eight SB623 lots compared with their MSCs.
HGF expression exhibited great variability among donorsTable 2 SB623-to-parental MSC ratios of mRNA expression lev
FGF1 FGF2 FGFR1 FGFR2 B
SB623/MSC expression 1.3a 1.7a 0.7a 0.2a N
SD 0.27 0.47 0.13 0.08 N
Cp 28 26.5 26 27 3
Values represent averaged ratios obtained from qRT-PCR data on eight pairs of MSC
MSC/SB623 pairs were used. SD, standard deviation; Cp, crossing point (threshold P(values differed up to 30-fold) and between pair members
(in SB623 cells, it was either up or down, compared with
MSCs).
Effects of neutralization and silencing of human growth
factors on rat neural cell growth
Previously, we demonstrated that FGF2 is the major medi-
ator of MSC- and MSC-CM-driven rat nestin induction in
rat cortical cells/MSC cocultures [14]. Here we confirmed
these results for SB623 cells: indeed, the anti-FGF2 block-
ing (bFM1), but not nonblocking (bFM2) monoclonal
antibody, completely abrogated SB623-CM-driven nestin
increase at 200 ng/ml and partially at 20 ng/ml (CM was
used at 25%) (Figure 2A).
We also tested the contribution of FGF1 to the nestin
increase in MSC cocultures (Figure 2B). FGF1-blocking
antibody at 5 μg/ml completely abrogated the nestin
increase driven by 5 ng/ml of recombinant FGF1, but
not of FGF2. At the same concentration, the antibody
only partially decreased the inductive effects of MSCs
and MSC-CM. This suggested that human FGF1 was a
contributing stimulus to the MSC- and SB623-driven
nestin increase.
Rat GFAP expression in SB623 cocultures was reduced
in a concentration-dependent manner by the addition of
noggin protein, an antagonist of several BMPs, including
BMP2 and BMP4 [23]. This indicated that SB623-driven
rat GFAP expression in cocultures was mediated mainly
by human BMPs (Figure 2C).
Although HGF expression was not consistently changed
in SB623 cells compared with parental MSCs, it greatly
varied between different cell lots. We decided to test hu-
man HGF contribution to the promotion of neurogenesis
in cocultures, with the thought that if the contribution is
substantial, then selecting MSCs with high HGF expres-
sion levels and using them for SB623 production might be
beneficial. Human HGF was efficiently silenced by using
siRNA: a very low residual HGF expression was found on
day 6 after transfection. The next day after the transfection
with either HGF siRNA (siHGF) or control RNA (siCon-
trol), transfected cells were used in cocultures with rat
neural cells. After 5 days of coculturing, the expression
levels of rat neural markers and human GAP were deter-
mined. Both Nes and GFAP levels were similar between
siHGF and siControl cocultures, whereas CNP levels were
reduced by about 75% to 85%. However, we noticed thatels
MP2 BMP4 BMP6 HB-EGF EGF HGF GAP
D 3.6a 1.6 0.9 1.5 0.7
D 2.27 1.19 0.47 0.75 0.72
5 30 33 29 30.5 31 21
s and SB623 for all factors, except for BMP2 and BMP6, where data from six






























































































Figure 2 Role of human growth factors in induction of rat neural markers in various culture settings; qRT-PCR. (A) Effect of FGF2
inhibition on rat nestin. Rat neural cells were stimulated with SB623 cell-derived conditioned medium (25%), which increased the nestin expression.
The presence of FGF2-neutralizing antibody (bFM1), but not FGF2-specific nonneutralizing antibody (bMF2), concentration-dependently inhibited the
nestin increase. (B) Effect of human FGF1 inhibition on rat nestin. Rat neural cells were stimulated by MSCs (60 or 200 cells/well), MSC-CM (5%),
or recombinant FGF1, or FGF2 (both at 5 ng/ml), which led to the induction of rat nestin. The application of the anti-human FGF1 neutralizing
antibody decreased nestin mRNA levels induced by all stimuli but the recombinant FGF2. (C) Effect of BMP inhibition on rat GFAP induction.
Rat GFAP was induced by coculturing rat neural cells with SB623 (200 cells/well). A BMP inhibitor noggin concentration-dependently decreased
the GFAP induction. (D) Effect of HGF silencing in MSC on rat CNP induction. Rat CNP expression was stimulated by coculturing rat neural cells with
MSC transfected with either HGF siRNA (siHGF) or control siRNA (siControl). A lower CNP induction was observed in cocultures with siHGF-transfectants.
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expression by 25% to 50%, likely reflecting the reduced pro-
liferation of siHGF transfectants. After normalization to
huGAP, the relative expression levels of rat CNP showed a
decrease (Figure 2D), and Nes and GFAP levels showed
some increase (not shown) in cocultures with siHGF trans-
fectants, compared with corresponding expression levels in
cocultures with siControl transfectants. The silencing was
performed on both MSCs and SB623, with very similar re-
sults. Furthermore, transfection of MSCs with either con-
trol siRNA or HGF siRNA resulted in a 20% to 30%
decrease in the numbers of cells harvested after 6-day cul-
turing, as compared with nontransfected cells. The num-
ber of harvested HGF transfectants was slightly smaller
than that of the transfected control (see Additional file 5:
Figure S4A). All three groups showed approximately 97%
viability at harvesting. These results indicated that the
HGF silencing likely slowed the cell proliferation more
than the control transfection, which could explain the re-
duction observed in the total GAP expression in siHGF
transfectants, as compared with the control.We also tested siHGF and siControl transfectants for
mRNA expression levels of a set of genes encoding
growth factors (HGF, FGF2, HB-EGF, BMP6), ECM pro-
tein (LAMA4), enzyme TGM2, and another housekeep-
ing protein (GDI), at two time points (Additional file 5:
Figure S4B). Although HGF expression was strongly de-
creased in siHGF compared with siControl transfectants
at both time points, none of the other tested genes showed
downregulation. This confirmed that HGF silencing was
specific. We concluded that human HGF was partly re-
sponsible for the induction of CNP, but not Nes or GFAP,
in the cocultures.
Effects of SB623 and MSCs on development of
hemisynaptic puncta in neurons
We previously observed an approximately twofold in-
crease of two rat neuronal markers: microtubule-
associated protein 2 and Doublecortin, in cocultures with
MSCs [14]. This was not, however, a sufficiently robust in-
crease to permit the comparison of MSCs with SB623
(Additional file 1: Figure S1). Therefore, to compare the
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neuronal lineage, we decided to use a more advanced
differentiation characteristic, the development of pre-
synaptic puncta, which were detected by the immuno-
staining of vesicle glutamate transporter (VGAT) and
vesicle GABA transporter (VGAT), and by their distri-
bution along neurites. The presence of either MSC or
SB623 expedited the appearance of punctated VGLUT
staining (most of the neurons stained positively) and, a
few days later, punctated VGAT staining (Figure 3A).
To compare quantitatively the effects of MSCs with
those of SB623, we assessed the distribution of pre-
synaptic puncta along neurites. No significant difference
in the density of VGLUT puncta per neurite length was
found in MSC- and SB623-cocultures (compared on day
8, not shown). However, we observed a significant in-
crease (about 30%) in numbers of VGAT puncta per
neurite length in SB623 cocultures, compared with
MSC cocultures or with neural cells alone (Figure 3B).
As shown on Figure 3C, in SB623 cocultures, VGAT
puncta were also brighter and more regularly spaced































Figure 3 Comparison of presynaptic puncta formation in
cocultures of rat embryonic neural cells with MSCs or SB623;
immunostaining. (A) Immunostaining for VGLUT (day 7) and VGAT
(day 11); rat/human cell ratio, 50:1. Bar, 50 μm. (B) Quantification of
VGAT-immunoreactive puncta per neurite length (averaged from
10 microscopic fields, one to four neurites/field), day 11. (C) Typical
distribution and size of VGAT-positive puncta in axonal processes in
cocultures with MSCs (upper) or SB623 (lower), day 13. Neurites are
outlined manually. Bar, 50 um.Nes+-cell growth on MSC- and SB623-derived ECM
We previously demonstrated that ECM derived from
SB623 supports a more robust growth of neural cells, as
measured by the LDH activity in cell lysates after 2- to
3-week culturing [12]. Here we produced ECM from pairs
of MSCs and SB623 and plated rat neural cells on it for
the detection of nestin protein and mRNA. More
Nes+-cells appeared on SB623-, than on MSC-derived
ECM (Figure 4A), and counting showed a higher percent-
age of Nes+-cells on the SB623-ECM than on the MSC-
ECM (Figure 4B). Nes gene expression was also quantified
and normalized to the LDH activity released from MSCs
and SB623 cells (during the lysis of cell monolayers for
ECM preparation) to account for possible differences in the
number of ECM-producing cells (Figure 4C). Thus, the
quantification of both nestin immunostaining and mRNA
expression showed that substantially more Nes+-cells
were growing on SB623-ECM than on MSC-ECM.
TGM2 in MSC and SB623; TGM2 silencing in
ECM-producing cells reduces the ability of ECM to
support Nes+ cell growth
A proteomic analysis of MSC- and SB623-ECM by using
mass spectrometry [22] identified TGM2, an ECM cross-
linking enzyme, as present at higher levels in SB623-ECM.
Expression analysis confirmed systematically higher levels
of TGM2 mRNA in SB623 than in MSC (in four of
five donor-cell pairs) (Figure 5A). Next, we conducted
a TGM2 enzymatic activity assay measuring the crosslink-
ing of biotinylated cadaverine to PLL-coated microplate
in the presence of total MSC or SB623 cell lysates. The
activity was normalized to the total cell protein. The assay
was TGM2-specific, because a TGM2-blocking antibody
significantly reduced the incorporation of biotinylated
cadaverine (not shown). The enzymatic activity assay
demonstrated a higher crosslinking activity of SB623- than
of MSC-lysates (Figure 5B). With immunoblotting, we also
confirmed that in the majority of donor cell pairs tested,
more TGM2 was found in SB623-ECM than in MSC-
ECM (Figure 5C, Additional file 6: Figure S5).
To clarify whether ECM-bound TGM2 affects neural cell
growth, SB623 cells were transfected with either TGM2-
siRNA (siTGM2) or control siRNA, replated on the next
day, and cultured for 7 days. The transfection with TGM2-
siRNA effectively and specifically silenced the expression
of TGM2: on day 7, residual TGM2 expression was around
5% of that of the control (not shown). After 7 days, one
plate was used to purify ECM, and a duplicate plate
was used in an LDH assay to generate data for the
normalization to the number of ECM-producing cells.
The ECM produced by siTGM2-transfectants, but not
by siControl transfectants, was significantly more fra-
gile (easily detachable) and required extreme care. We
were unable to purify siTGM2-ECM from two of five
Figure 4 Comparison of SB623- and MSC-derived ECM in supporting nestin-positive cell growth. (A) Rat neural cells were grown for
5 days on MSC- or SB623-derived ECM and then immunostained for nestin (upper panel) and counterstained for nuclei (lower panel); magnification
100×. (B) Nestin-positive cells grown and stained as described in (A) were counted, and their numbers expressed as percentage of total nuclei. (C) Rat
nestin expression in cells growing on MSC- or SB623-ECM was quantified by using qRT-PCR and normalized by the LDH activity released from either
MSC- or SB623-ECM-producing cells during ECM preparation, correspondingly, to account for possible differences in cell numbers.
Figure 5 Comparison of expression and activity of TGM2 in SB623 and MSC; its functional analysis in ECM using siRNA. (A) Expression
levels of TGM2 normalized to GAP were determined by using qRT-PCR in SB623/MSC pairs from several donors. Levels in SB623 cells were
expressed relative to levels in parental MSCs, which were set on 1. (B) TGM2-crosslinking activity was measured by amounts of biotinylated
cadaverine incorporated into PLL in the presence of SB623 or MSC cell lysates. The activity was then normalized to the total protein, and
expressed compared with the parental MSCs, where the values were set on 1. (C) TGM2 was detected in ECM of MSCs and SB623 by using
immunoblotting. The TGM2 signal was quantified densitometrically and normalized to the total ECM protein per lane. The total ECM protein
was assessed by using duplicated gel: the gel was stained for protein; photographed; and the density of corresponding lane minus background
determined. (The whole blot and gel are shown in Additional file 6: Figure S5). (D) Nestin expression was quantified by using qRT-PCR in rat
neural cells grown on ECM produced by SB623 transfected with either siTGM2 or siControl. Nestin levels on siControl-ECM were set on 1.
The graph represents means from three experiments; error bar represents standard error of mean; *P < 0.05. (E) Rat nestin mRNA expression
in cocultures with either siTGM2 or siControl transfectants. The graph represents mean from two experiments.
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Successfully purified siTGM2- and siControl-ECMs
(fully intact under the microscope) were used as sub-
strates for rat embryonic cortical cells. After 5 to 7 days,
rat nestin mRNA was measured and normalized to the
LDH from ECM-producing cells. The normalized rat
nestin mRNA expression was lower in cultures grown on
siTGM2-ECM than in those grown on siControl-ECM
(Figure 5D), indicating that the ECM produced by cells
with silenced TGM2 had a decreased ability to support
the growth of neural precursors.
We also tested the ability of siTGM2- and siControl
transfectants to stimulate neuropoiesis in cocultures with
rat neural cells (human/rat cell ratio was up to 1:10), and
no difference in Nes levels was found (Figure 5E). This
observation indicated that TGM2 silencing did not im-
pact the ability of cells to mediate trophic support for
Nes+-cells and also suggested that the transfectants’
health was comparable to that of the control. Indeed,
although compared with the siControl transfectants,
siTGM2 transfectants exhibited a slightly reduced cell
proliferation (which is in agreement with a previous
report [24]), no effect on the cell viability was found
(Additional file 7: Figure S6A). When mRNA levels in
siTGM2 were tested at days 2 and 6 after transfection
and compared with corresponding levels in siControl
cells, TGM2-siRNA transfectants showed substantial
decreases in the level of TGM2, but did not show a de-
creased gene expression in a panel of other tested genes
encoding growth factors HGF, FGF2, HB-EGF, and BMP6,
ECM protein LAMA4, and the housekeeping protein GDI
(Additional file 7: Figure S6B). This confirmed that the si-
lencing of TGM2 was specific.
Discussion
Here we present in vitro data indicating that SB623 cells,
MSC derivatives, which are in development as a therapy
for intracranial transplantations in the treatment of
chronic stroke, more effectively stimulate neuropoietic
responses and presynapse formation in neural cells than
do their parental MSCs. We identified several factors
that contribute to this difference.
To compare quantitatively the neuropoietic potency of
SB623 cells with that of their parental MSCs, we adapted
a previously characterized microplate neuropoiesis assay
[14]. When rat neural cells are cocultured with human
MSCs or SB623 cells at cell-plating densities within a
previously determined linear range of the assay, rat neural
cell proliferation and differentiation depend on the num-
ber of human cells. Therefore, at these conditions, ratios
of rat neuromarker expression levels to human house-
keeping gene-expression levels are constant and reflect
the intrinsic potency of human cells to stimulate the rat
neuromarker. These ratios, averaged from cocultures withseveral human cell-plating densities, are referred to as
neuropoietic coefficients (Figure 1). Using neuropoietic
coefficients allowed us to compare quantitatively six
lots of SB623 cells with parental MSCs in their ability to
promote the expression of rat neural progenitor marker
(nestin), oligodendrocyte (CNP), and astrocyte (GFAP)
markers in cocultures (Table 1).
The comparison of neuropoietic coefficients from SB623
with parental MSCs reveals a strong trend that suggests
a higher neuropoietic activity of SB623 than of parental
MSCs. Indeed, the majority of individual comparisons
show SB623 having the higher coefficients. No differ-
ences between SB623 and MSC were observed in a few
instances. In no comparison was MSC found to have a
higher neuropoietic coefficient than its derivative SB623.
A larger sample size, including repeated isolations from
individual donors, will be required to assess the statistical
significance of these observations. Our conclusion is that
SB623 cells tend to show improved neuropoietic potency,
compared with their parental MSCs, especially with re-
spect to stimulating oligodendrogenesis and neural pro-
genitor growth.
The introduction of “neuropoietic coefficients” here
serves an immediate goal of comparing genetically modi-
fied MSCs with the parental MSCs with respect to one
particular mechanism of action: the support of neuropoi-
esis. Our work could be regarded as a preliminary attempt
to introduce a multiparametric measure of cell potency.
This approach, however, should be further refined with re-
gard to standardization of measurements and correlation
with the in vivo activity. The need for such approach is
dictated by the complex nature of cell therapy, and the ul-
timate goal is to develop a scoring system that can be used
as a predictor for the in vivo potency.
MSCs secrete various factors with neuropoietic proper-
ties [6,25-27]. Tate et al. [13] identified trophic factors in
conditioned media derived from MSC/SB623 pairs. We
previously implicated human FGF2 as a major soluble me-
diator of the MSC-driven rat nestin increase in cocultures
[14]. Here we showed that SB623 cells express FGF2
mRNA at higher levels (Table 2), and some SB623 lots
secrete FGF2 at higher levels than do MSCs (in four of six
pairs) (Additional file 4: Figure S3). Although the crucial
role of FGF2 for the maintenance of neural stem cells is
well known, we have shown here that small numbers of
MSCs and SB623 cells can provide sufficient FGF2 quan-
tities to drive neuropoiesis in a surrounding neural cell
population. It is interesting that among three donors that
had highest SB623/MSC Nes coefficient ratios, only one
showed an increased FGF2 secretion in SB623 over MSCs,
which supports the hypothesis that many factors deter-
mine the neuropoietic potency of a cell lot.
Other factors do contribute as well. An FGF1-blocking
antibody partially reduced nestin increases driven by
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(Figure 2B) or of SB623 (not shown), but it had no ef-
fect on nestin increase driven by recombinant FGF2
(Figure 2B), indicating that the result is not caused by
cytotoxicity. FGF1 expression in SB623 was found to
be reproducibly higher than in MSC (Table 2). FGF1 is
the only known FGF ligand of all four FGF receptors
(FGFRs). It has been implicated in promoting neuronal
maturation, rather than neurogenesis [28,29], and has
demonstrated an effectiveness in an animal model of
stroke by promoting neurogenesis and angiogenesis in
rats [30]. FGF2 and FGF1 roles illustrate the potentially
beneficial characteristic traits of MSC-based therapeutics:
the redundancy and adaptability of their signals to vari-
ous sets of receptors expressed by the surrounding cell
population.
In SB623 cells, we observed a profound downregula-
tion of FGF receptor FGFR2 and a mild, but reprodu-
cible, downregulation of FGFR1 expression. FGFR1 and
FGFR2 are major FGF receptors expressed by cultured
MSCs [31], and their downregulation may signify sev-
eral things: (a) it can explain the slower growth of
SB623 cells compared with MSCs [10], (b) it can be a
senescence-associated trait [31]; (c) it can drastically re-
duce the FGF uptake by SB623 cells, thus increasing the
FGF availability to the surrounding neural cells; (d) it
may also represent a negative-feedback mechanism trig-
gered by the forced expression of the exogenous NICD1
[32], a hypothesis that must be explored in subsequent
studies.
SB623 cells exhibit increased levels of the BMP4 ex-
pression (Table 2). Noggin, a potent antagonist of several
BMPs, including BMP2 and BMP4, as well as BMP5,
BMP7, BMP13, and BMP14 (but not of BMP3, −6, –9–12,
and −15) [23], significantly reduced rat GFAP levels in co-
cultures with SB623 (Figure 2C), indicating that noggin-
inhibitable BMPs contributed to astrocyte stimulation
by SB623, similar to their role in MSCs [14]. Interplay
between FGF2 and BMP has been shown to control the
self-renewal, dormancy, and differentiation of rat neural
stem cells [33]. In our study, recombinant FGF2 and
BMP4 had opposite effects on nestin-positive, as well as
on GFAP-positive cells (not shown). Interestingly, the
aggregated effect of the increased production of both of
these “opposing” factors, as in SB623, boosted the over-
all neural cell growth.
MSC-produced HGF has been implicated in promoting
the development of oligodendrocytes and neurons in a
multiple sclerosis model [34]. HGF was not systematically
affected by the SB623 manufacturing process, and its
expression levels were highly variable among donors.
We showed here that in cocultures, the silencing of the
human HGF in SB623 cells (Figure 2D) or MSCs (not
shown) partially inhibited the human-cell-mediatedCNP, but not the nestin or GFAP increases. Moreover,
the HGF silencing even resulted in some increases in
nestin and GFAP induction, which could reflect a shift
in the glia differentiation balance. These results indi-
cated that human HGF is one of the stimuli that induce
the rat oligodendrocytic marker CNP; however, other
factors participate as well in the strong induction of
CNP observed in SB623-driven cocultures.
We also observed that VGAT-puncta (inhibitory hemi-
presynapses) were bigger and significantly more densely
spaced along neurites in SB623 cocultures than in MSC
cocultures, suggesting that SB623 cells are superior in
promoting the GABAergic presynaptic maturation in rat
embryonic neurons (Figure 3). We did not find statistically
significant difference between the density of VGAT puncta
in MSC cocultures and in neural cells alone, which
seemingly disagreed with Mauri et al. [16]. Mauri et al.
compared the effects of MSCs and astrocyte monolayers
(in indirect cocultures) on both VGAT protein expression
and on GABA-ergic transmission in rat embryonic hippo-
campal neurons and found the superior effects of MSCs.
The lack of MSC effect in our study can be explained by
(a) much weaker stimuli we used in our co-cultures; our
plating densities were equivalent to <5% of the MSC
monolayer, and by (b) differences in the detection: they
quantified total immunofluorescence, whereas we counted
hemisynapses.
However, at early time points, we did clearly see that in
the presence of both MSCs and SB623, a diffuse VGAT
staining was promoted. Mediators of VGAT stimulation
were not identified here. Previously, BDNF was implicated
in MSC effects on the GABAergic transmission [16]. Our
preliminary experiments do not support the role of BDNF
in our system. This may be explained by the very low
ratios of human to rat neural cells used in this system
as compared with the one described in [16].
Other factors, like FGFs, could also contribute to the
enhanced effects of SB623 compared with those of MSC
[18]. The enhancement of the inhibitory synapse forma-
tion might be an additional benefit of SB623 transplanta-
tions in parkinsonism, epilepsy, and movement deficits in
postischemic encephalopathy, which are associated with
an impairment of the GABAergic system [35].
We previously showed that SB623 cell-derived ECM
supports the growth of embryonic neural cells better than
does ECM derived from parental MSCs, as measured by
intracellular LDH after long-term culturing [12]. Here we
supplemented this observation by showing that SB623-
ECM supports more robust growth of nestin-positive
neural precursors than does MSC-ECM; and that the dif-
ference can be detected within 5 days (Figure 4). Import-
antly, in the present study, we used CellBIND microplates,
which are superior to regular tissue culture plates in pro-
viding the attachment for both SB623-ECM and fragile
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neurosupportive properties of ECMs did not result from
partial losses of MSC-ECM during the purification.
We hypothesize that both the observed structural ro-
bustness and the enhanced neurosupportive property of
SB623-ECM, compared with those of MSC-ECM, could
be a function of the same ECM molecule, tissue trans-
glutaminase (TGM2). Indeed, four of five SB623 lots
expressed more TGM2 mRNA, and the crosslinking activ-
ity of all SB623 cell lysates was higher than that of MSC
lysates. We confirmed that more TGM2 is present in
SB623-derived ECM than in MSC-derived ECM (Figure 5).
When TGM2 expression was efficiently silenced (by using
siRNA), the ECM produced by SB623 cells with silenced
TGM2 supported less nestin-positive cell growth than did
the control ECM (Figure 5D). In a coculture setting, how-
ever, neuropoietic properties of SB623 were not affected
by the TGM2 silencing (Figure 5E). These facts suggested
that TGM2 mediated its effect on neural precursors when
it was ECM-associated, rather than cell surface-associated
or intracellular. Also, the silencing of TGM2 was fairly
specific, and the transfectants did not exhibit global health
issues compared with the control transfectants (Additional
file 7: Figure S6).
These observations implicate TGM2 in the improved
neuropoietic activity of SB623 ECM; however, the nature
of its contribution remains unclear. We speculate that the
ECM-associated TGM2 could promote neural cell growth
in ECM-based cocultures by means of enzymatic cross-
linkng activity and nonenzymatic adapter/scaffolding
function. Indeed, the cell-surface TGM2 nonenzymatically
promotes a rapid assembly of fibronectin and remains as-
sociated with fibronectin fibrils [36]. This event initiates
the assembly and crosslinking of other components of
ECM including fibrin, fibronectin, collagen, vitronectin,
and osteopontin [37]. This way, TGM2 increases ECM
stability and the rigidity of crosslinked fibronectin and
collagen fibrils. Several reports emphasized that substrate
stiffness per se can govern the fate of neural stem cells
[38-40]. They showed that neural cell proliferation favors
soft substrates, neuronal differentiation even softer ones,
whereas oligodendrogenesis needed stiffer substrates. This
seeming contradiction, that presumably stiffer SB623-
ECM exhibits superior neuropoietic properties to those of
MSC-ECM, could be resolved if we consider the other
consequences of TGM2-crosslinking activity: unmasking
cryptic binding sites within ECM molecules for other
ECM components and cell-surface receptors, such as
integrins [41,42]. Besides, TGM2 deposited in ECM binds
with high affinity to heparin sulfate moieties of syndecan-
4 [43]. Both integrins and syndecan-4 are essential for the
adhesion, survival, and proliferation of nestin-positive
neural cells and are colocalized with neural stem cells in
brain development [19,44,45]. Thus, neural precursorsand differentiating cells could benefit from an increased
activity and enhanced incorporation of TGM2 into ECM
as observed in SB623 cells in numerous ways. Moreover,
the higher expression of TGM2 can also be beneficial for
the survival of transplanted SB623 themselves. Indeed,
TGM2-overexpressing MSC showed an improved survival
after transplantation when used in a myocardial injury
model [24]. Interestingly, another crosslinking enzyme
secreted to the medium, quiescin sulfhydryl oxidase 1,
was recently reported to participate in laminin incorp-
oration to ECM and thus be required for cell adhesion
and migration [46].
Conclusions
The data presented here demonstrate that MSC-derived
cells, SB623, which are in development for intracranial
transplantations to treat stable stroke, are typically more
potent than their parental MSCs in stimulating the growth
and differentiation of neural precursors. This increased
neuropoietic potency of SB623 observed in cocultures
with rat embryonic cortex cells can be attributed to the in-
creased expression of FGF1, FGF2, and BMPs in SB623 as
compared to MSCs. The presented data also indicate that
the ECM produced by SB623 promotes a more efficient
neural precursor growth than does the ECM produced by
MSC, which can be at least partly explained by higher ac-
tivity and expression levels of an ECM crosslinking en-
zyme, TGM2, observed in SB623 compared with parental
MSCs. The enhanced neuropoietic potential of SB623
could be beneficial in a neurodegenerative application,
where the stimulation and support of endogenous neural
precursors constitute one of the proposed mechanisms of
action of cell therapeutic transplantations. Further studies
are required to determine how genetic manipulation and
other manufacturing steps contribute to the creation of
this new phenotype of SB623.
Additional files
Additional file 1: Figure S1. Immunodetection of neurons in
cocultures. Cocultures described in Figure 1 were stained for MAP2, and
counterstained with DAPI on day 5 and day 9 of culturing. No difference
between MSC and SB623 cocultures was detected in either numbers of
mature neurons or their dendrite outgrowth at these time points.
Additional file 2: Figure S2. Quantification of immunostaining of
nestin, GFAP, and CNP in cocultures. Neural cells were cultured either
alone or with MSC or SB623 (Donor D) at rat to human cell ratio 20:1
Cultures were immunostained for either nestin or GFAP on day 5 or CNP
on day 12; and counterstained with DAPI. Immunofluorescence signal
from each neuromarker was quantified by using ImageJ and results
expressed as immunofluorescence per positive cell. Error bars represent
the standard deviation between four fields, from duplicated cultures.
*P < 0.05.
Additional file 3: Table S1. Ratios of mRNA expression by donor,
SB623/MSC.
Additional file 4: Figure S3. FGF2 secretion by MSC and SB623, ELISA.
Neurobasal medium was conditioned by confluent MSC or SB623 layers
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using the R&D System Duo set of antibodies, MaxiSorp plates (Nunc), and
recombinant FGF2 from Peprotech for standard curve. After the removal
of the conditioned medium, cells were lysed in 2% Triton, and LDH in
lysates was quantified as a surrogate for cell-number determination. The
graph shows FGF2 concentrations normalized to LDH. All samples in this
graph were analyzed in the same experiment.
Additional file 5: Figure S4. Comparison of vital functions in HGF and
control siRNA transfectants. (A) MSCs were transfected with either HGF
siRNA (siHGF) or control siRNA (siControl) or not transfected at all; next
day, they were replated and grown for additional 5 days (6 days after
transfection) in six well plates, then harvested and counted by using
trypan blue to determine the total numbers of harvested cells and their
viability. The number of harvested transfectants was expressed as
percentage of harvested not-transfected cells. Error bars represent
standard deviations in duplicated samples. (B) MSCs transfected as above
were replated in 96-well plates in quadruplicates and grown for a total of
3 and 6 days after transfection. On indicated days cells were lysed by
using SideStep Lysis buffer and replicas were combined pair-wise,
resulting in biologic duplicates. One-step qRT-PCR was performed on
water-diluted samples using preoptimized Taqman assays; and results
were normalized to GAP. The expression level of each gene in Control
siRNA transfectants (siControl) was set on 1, and the level in HGF siRNA
transfectants was expressed correspondingly. Error bars represent
standard deviations between biologic duplicates.
Additional file 6: Figure S5. TGM2 in ECM in two pairs of MSC/SB623.
Two duplicated gels were electrophoresed; and one was transferred for
immunoblotting with TGM2 antibody, whereas another one was stained
for protein. Labels on irrelevant samples are omitted. TGM2 antibody
detected a single band in ECM, around ~80 kDa. Both blot and gel were
analyzed densitometrically.
Additional file 7: Figure S6. Comparison of vital functions in TGM2
and control siRNA transfectants. (A) SB623 were transfected with either
TGM2 siRNA (siTGM2) or control siRNA (siControl) or not transfected at all;
on the next day, cells were replated and grown for additional 5 days
(6 days after transfection) in six-well plates, then harvested and counted
by using trypan blue to determine the total number of harvested cells
and their viability. The number of harvested transfectants was expressed
as a percentage of harvested not-transfected cells. Error bars represent
standard deviations in duplicated samples. (B) SB623 transfected as
described were replated in 96-well plates in quadruplicates and grown
for total 3 and 6 days after transfection. On indicated days cells were
lysed by using SideStep Lysis buffer, and replicas were combined pair-wise
resulting in biologic duplicates. One-step qRT-PCR was performed on
water-diluted samples by using preoptimized Taqman assays; and
results were normalized to GAP. The expression level of each gene in
Control siRNA transfectants (siControl) was set on 1, and the level in
TGM2 siRNA transfectants was expressed correspondingly. Error bars
represent standard deviations between biologic duplicates.Abbreviations
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